Nevertheless, the use of MCT1 inhibitors protected BEAS-2B from SeChry@PUREG4-LA24 toxicity and it may be a strategy to protect non-cancer cells in a systemic application of the nanoformulation. This evidence concerns the gene SLC16A1 and cancer.